Atea Pharmaceuticals Company Insiders

AVIR Stock  USD 3.41  0.07  2.01%   
Atea Pharmaceuticals employs about 56 people. The company is managed by 15 executives with a total tenure of roughly 131 years, averaging almost 8.0 years of service per executive, having 3.73 employees per reported executive. Discussion of Atea Pharmaceuticals' management performance can provide insight into the enterprise performance.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atea Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in Atea Stock, please use our How to Invest in Atea Pharmaceuticals guide.

Atea Pharmaceuticals' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Atea Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Atea will maintain a workforce of slightly above 60 employees by February 2026.
 
Covid

Atea Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.2386) % which means that it has lost $0.2386 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3798) %, meaning that it created substantial loss on money invested by shareholders. Atea Pharmaceuticals' management efficiency ratios could be used to measure how well Atea Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 01/07/2026, Return On Tangible Assets is likely to drop to -0.34. In addition to that, Return On Capital Employed is likely to drop to -0.41. At this time, Atea Pharmaceuticals' Total Assets are relatively stable compared to the past year. As of 01/07/2026, Total Current Assets is likely to grow to about 535.3 M, while Net Tangible Assets are likely to drop slightly above 398.8 M.
As of 01/07/2026, Common Stock Shares Outstanding is likely to drop to about 80.8 M. In addition to that, Net Loss is likely to grow to about (99.1 M)
Atea Pharmaceuticals holds a total of 78.13 Million outstanding shares. The majority of Atea Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Atea Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Atea Pharmaceuticals. Please pay attention to any change in the institutional holdings of Atea Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
 
Shares in Circulation  
First Issued
2017-12-31
Previous Quarter
83.7 M
Current Value
79.1 M
Avarage Shares Outstanding
69.4 M
Quarterly Volatility
23.3 M
 
Covid
Some institutional investors establish a significant position in stocks such as Atea Pharmaceuticals in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Atea Pharmaceuticals, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Atea Pharmaceuticals Workforce Comparison

Atea Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 1,586. Atea Pharmaceuticals holds roughly 56.0 in number of employees claiming about 4% of equities under Health Care industry.

Atea Pharmaceuticals Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atea Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atea Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Atea Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
1.0
2
2
 25,000 
 25,000 
2024-06-01
2.25
18
8
 623,700 
 217,450 
2024-03-01
1.0
12
12
 1,691,736 
 499,784 
2020-12-01
0.3443
21
61
 16,446,374 
 18,528,149 

Atea Pharmaceuticals Notable Stakeholders

An Atea Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Atea Pharmaceuticals often face trade-offs trying to please all of them. Atea Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Atea Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Andrea JDExecutive CFOProfile
Kerry GagnonVP QualityProfile
CPA CPAExec OfficerProfile
XiaoJian ZhouExecutive DevelopmentProfile
Jayanthi WolfExecutive AffairsProfile
Wayne CPAExecutive OfficerProfile
Ariyapadi KrishnarajVice MarketingProfile
JeanPierre SommadossiChairman, FounderProfile
John VavrickaChief OfficerProfile
Nancy AgrawalExecutive DevelopmentProfile
Qi HuangSenior VirologyProfile
Maria MDChief OfficerProfile
Jonae BarnesSenior CommunicationsProfile
Keith PietropaoloExecutive ManagementProfile
Adel MoussaExecutive ChemistryProfile
String symbol = request.getParameter("s");

About Atea Pharmaceuticals Management Performance

The success or failure of an entity such as Atea Pharmaceuticals often depends on how effective the management is. Atea Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Atea management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Atea management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.33)(0.34)
Return On Capital Employed(0.39)(0.41)
Return On Assets(0.33)(0.34)
Return On Equity(0.44)(0.42)

Atea Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Atea Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Atea Pharmaceuticals within its industry.

Atea Pharmaceuticals Manpower Efficiency

Return on Atea Pharmaceuticals Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee3M
Net Loss Per Executive11.2M
Working Capital Per Employee7.9M
Working Capital Per Executive29.6M

Additional Tools for Atea Stock Analysis

When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.